Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chondroitin Sulfate for Treatment of NEC
NCT06547424Phase 1Withdrawn
- Sponsor
- Indiana University
- Start
- Jan 2025
- Primary completion
- Dec 2028
- Modality
- Biomacromolecule, Polysaccharide, GAG (Glycosaminoglycan)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in necrotizing enterocolitis (NEC) comparing Chondroitin sulfate with Placebo (2 arms). Primary endpoints: All-cause mortality at 28 days and Progression to need for surgery at 28 days. Planned start Jan 2025; status: withdrawn.
02
Drugs
chondroitin sulfate
03
Conditions
necrotizing enterocolitis (NEC)
Beyond the preview
Go deeper on NCT06547424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547424.